{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,13]],"date-time":"2026-05-13T12:07:56Z","timestamp":1778674076357,"version":"3.51.4"},"reference-count":18,"publisher":"Czech Society of Ophthalmology of the CzMA","issue":"AoP","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Cesk Slov Oftalmol"],"published-print":{"date-parts":[[2025,1,17]]},"abstract":"<jats:p>Aims: This scoping review was conducted to investigate whether nocturnal eye compression from inappropriate sleeping postures may contribute to the development or asymmetry of keratoconus (KC), by examining the association between sleeping positions and KC.\n\nMaterial and Methods: A systematic search of CENTRAL, MEDLINE, EMBASE, LILACS, ClinicalTrials.gov, gray literature, and selected journals from inception to January 18, 2023, was undertaken.\n\nResults: Ten studies involving 2 322 participants met inclusion criteria. These studies were categorized into analytical and non-analytical designs to evaluate the relationship between prone, lateral, or supine sleeping positions and KC presence or asymmetry. Among the included studies, 50% were non-analytical, all indicating a correlation between KC parameters and nocturnal eye compression. In contrast, a statistically significant association between sleeping positions and KC risk was reported in 3 out of 5 analytical studies (60%).\n\nConclusion: Findings suggest a possible link between prone or lateral sleeping positions and KC development or asymmetry, implying that these positions may increase corneal biomechanical stress during sleep. However, the association was confirmed in only 60% of analytical studies. The review highlights the necessity for additional research to validate these findings and to explore potential causal mechanisms between sleeping positions and KC.<\/jats:p>","DOI":"10.31348\/2025\/6","type":"journal-article","created":{"date-parts":[[2025,1,21]],"date-time":"2025-01-21T08:51:30Z","timestamp":1737449490000},"source":"Crossref","is-referenced-by-count":2,"title":["Sleeping Behavior and Keratoconus: A Scoping Review"],"prefix":"10.31348","author":[{"given":"Alejandro","family":"Tello","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Paula Alejandra","family":"Navarro","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Angelica","family":"Pedraza-Concha","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sylvia Juliana","family":"Villamizar","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Virgilio","family":"Galvis","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"16213","published-online":{"date-parts":[[2025,1,17]]},"reference":[{"key":"ref0","doi-asserted-by":"crossref","unstructured":"Daruich A, Bremond-Gignac D, Behar-Cohen F, Kermorvant E. R\u00e9tinopathie du pr\u00e9matur\u00e9: de la pr\u00e9-vention au traitement [Retinopathy of prematurity: from prevention to treatment]. Med Sci (Paris). 2020 Oct;36(10):900-907. French. doi: 10.1051\/medsci\/2020163 DOI: 10.1051\/medsci\/2020163","DOI":"10.1051\/medsci\/2020163"},{"key":"ref1","doi-asserted-by":"crossref","unstructured":"de las Rivas Ram\u00edrez N, Luque Aranda G, Rius D\u00edaz F, et al. Risk factors associated with Retinopathy of Prematurity development and progression. Sci Rep. 2020;12:21977. DOI: 10.1038\/s41598-022-26229-4","DOI":"10.1038\/s41598-022-26229-4"},{"key":"ref2","doi-asserted-by":"crossref","unstructured":"Hong EH, Shin YU, Cho H. Retinopathy of prematurity: a review of epidemiology and current tre-atment strategies. Clin Exp Pediatr. 2022 Mar;65(3):115-126. doi: 10.3345\/cep.2021.00773 DOI: 10.3345\/cep.2021.00773","DOI":"10.3345\/cep.2021.00773"},{"key":"ref3","doi-asserted-by":"crossref","unstructured":"Chiang MF, Quinn GE, Fielder AR, et al. International Classification of Retinopathy of Prematurity, Thi-rd Edition. Ophthalmology. 2021 Oct;128(10):e51-e68. doi: 10.1016\/j.ophtha.2021.05.031 DOI: 10.1016\/j.ophtha.2021.10.021","DOI":"10.1016\/j.ophtha.2021.05.031"},{"key":"ref4","doi-asserted-by":"crossref","unstructured":"Wilkinson AR, Adams GGW, Fleck BW, Nieto-Hernandez R; Guideline Development Groups (GDG) of the Royal College of Paediatrics and Child Health (RCPCH) and the Royal College of Ophthalmo-logists (RCOphth). UK screening and treatment of retinopathy of prematurity Updated 2022 Gui-delines. Ear-ly Hum Dev. 2023 Mar;177-178:105715. doi: 10.1016\/j.earlhumdev.2023.105715 DOI: 10.1016\/j.earlhumdev.2023.105715","DOI":"10.1016\/j.earlhumdev.2023.105715"},{"key":"ref5","unstructured":"Kanski\u2019s Clinical Ophtalmology 2020; p.538."},{"key":"ref6","doi-asserted-by":"crossref","unstructured":"Good WV; Early Treatment for Retinopathy of Prematurity Cooperative Group. Final results of the Ear-ly Treatment for Retinopathy of Prematurity (ETROP) randomized trial. Trans Am Ophthalmol Soc. 2004;102:233-248; discussion 248-520. DOI: 10.1093\/med\/9780190050726.003.0027","DOI":"10.1093\/med\/9780190050726.003.0027"},{"key":"ref7","doi-asserted-by":"crossref","unstructured":"Zobanov\u00e1 A, Brychc\u00ednov\u00e1 P, Autrata R, \u0160enkov\u00e1 K. Screening, Treatment and Long-term Observa-tion of Retinopathy of Prematurely Born Children in the Czech Republic. Cesk Slov Oftalmol. 2018;74(6):253-264. DOI: 10.31348\/2018\/6\/7","DOI":"10.31348\/2018\/6\/7"},{"key":"ref8","doi-asserted-by":"crossref","unstructured":"Strube YNJ, Wright KW. Pathophysiology of retinopathy of prematurity. Saudi J Ophthalmol. 2022 Oct 14;36(3):239-242. doi: 10.4103\/sjopt.sjopt_18_22 DOI: 10.4103\/sjopt.sjopt_18_22","DOI":"10.4103\/sjopt.sjopt_18_22"},{"key":"ref9","doi-asserted-by":"crossref","unstructured":"Wood EH, Chang EY, Beck K, et al. 80 Years of vision: preventing blindness from retinopathy of prema-turity. J Perinatol. 2021 Jun;41(6):1216-1224. doi: 10.1038\/s41372-021-01015-8 DOI: 10.1038\/s41372-021-01015-8","DOI":"10.1038\/s41372-021-01015-8"},{"key":"ref10","doi-asserted-by":"crossref","unstructured":"Yucel OE, Eraydin B, Niyaz L, Terzi O. Incidence and risk factors for retinopathy of prematurity in pre-mature, extremely low birth weight and extremely low gestational age infants. BMC Ophthal-mol. 2022 Sep 13;22(1):367. doi: 10.1186\/s12886-022-02591-9 DOI: 10.1186\/s12886-022-02591-9","DOI":"10.1186\/s12886-022-02591-9"},{"key":"ref11","doi-asserted-by":"crossref","unstructured":"Dogra MR, Vinekar A. Role of Anti-Vascular Endothelial Growth Factor (Anti-VEGF) in the Tre-atment of Retinopathy of Prematurity: A Narrative Review in the Context of Middle-Income Coun-tries. Pedi-atric Health Med Ther. 2023 Feb 15;14:59-69. doi: 10.2147\/PHMT.S391591 DOI: 10.2147\/phmt.s391591","DOI":"10.2147\/PHMT.S391591"},{"key":"ref12","doi-asserted-by":"crossref","unstructured":"Enr\u00edquez AB, Avery RL, Baumal CR. Update on Anti-Vascular Endothelial Growth Factor Safety for Reti-nopathy of Prematurity. Asia Pac J Ophthalmol (Phila). 2020 Jul-Aug;9(4):358-368. doi: 10.1097\/APO.0000000000000302 DOI: 10.1097\/apo.0000000000000302","DOI":"10.1097\/APO.0000000000000302"},{"key":"ref13","doi-asserted-by":"crossref","unstructured":"Sabri K, Ells AL, Lee EY, Dutta S, Vinekar A. Retinopathy of Prematurity: A Global Perspective and Re-cent Developments. Pediatrics. 2022 Sep 1;150(3):e2021053924. doi: 10.1542\/peds.2021-053924. PMID: 35948728 DOI: 10.1542\/peds.2021-053924","DOI":"10.1542\/peds.2021-053924"},{"key":"ref14","doi-asserted-by":"crossref","unstructured":"Autrata R, Krejc\u00edrov\u00e1 I, Senkov\u00e1 K, et al. Intravitreal pegaptanib combined with diode laser therapy for stage 3+ retinopathy of prematurity in zone I and posterior zone II. E J Ophthalmol. 2012 Sep-Oct;22(5):687-694. doi: 10.5301\/ejo.5000166 DOI: 10.5301\/ejo.5000166","DOI":"10.5301\/ejo.5000166"},{"key":"ref15","doi-asserted-by":"crossref","unstructured":"Fierson WM; American academy of pediatrics section on ophthalmology; american academy of ophthalmology; american association for pediatric ophthalmology and strabismus; american asso-ciation of certified orthoptists. Screening Examination of Premature Infants for Retinopathy of Prema-turity. Pediatrics. 2018 Dec;142(6): e20183061. doi: 10.1542\/peds.2018-3061. Erratum in: Pe-diatrics. 2019 Mar;143(3) DOI: 10.1542\/peds.2018-3810","DOI":"10.1542\/peds.2018-3810"},{"key":"ref16","doi-asserted-by":"crossref","unstructured":"Hartnett ME. Retinopathy of Prematurity: Evolving Treatment With Anti-Vascular Endothelial Growth Factor. Am J Ophthalmol. 2020 Oct; 218:208-213. doi: 10.1016\/j.ajo.2020.05.025, Erratum in: Am J Ophthalmol. 2021 Nov; 231:213 DOI: 10.1016\/j.ajo.2020.12.018","DOI":"10.1016\/j.ajo.2020.12.018"},{"key":"ref17","doi-asserted-by":"crossref","unstructured":"Wang Z, Zhang Z, Wang Y, Di Y. Effect of ranibizumab on retinopathy of prematurity: A meta-analysis. Front Pharmacol. 2022 Aug 22; 13:897869. doi: 10.3389\/fphar.2022.897869 DOI: 10.3389\/fphar.2022.897869","DOI":"10.3389\/fphar.2022.897869"}],"container-title":["Czech and Slovak Ophthalmology"],"original-title":[],"deposited":{"date-parts":[[2026,5,13]],"date-time":"2026-05-13T11:09:34Z","timestamp":1778670574000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.cs-ophthalmology.cz\/en\/journal\/articles\/352"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,1,17]]},"references-count":18,"journal-issue":{"issue":"AoP","published-online":{"date-parts":[[2025,1,1]]},"published-print":{"date-parts":[[2025,1,1]]}},"URL":"https:\/\/doi.org\/10.31348\/2025\/6","relation":{},"ISSN":["1211-9059","1805-4447"],"issn-type":[{"value":"1211-9059","type":"print"},{"value":"1805-4447","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,1,17]]}}}